EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets

08-Feb-2010 - Austria

EUCODIS Bioscience announced that it has received a cash injection of EUR 2 million from existing shareholders. The Company will use these funds to swiftly add new enzyme families to its product portfolio and to accelerate the development of international markets. At the same time, EUCODIS Bioscience is expanding its manufacturing capacity in pace with growing customer demand for its novel enzymes.

Commenting on the capital injection Thomas Fischer, CEO of EUCODIS Bioscience, said: "Following several product launches in 2009 and the recent expansion of our lipases family to 20 enzymes we continue to build our order book. Accordingly, our revenues will finance a good part of our expenses and investments this year."

Fischer continued: "Given the wealth of business opportunities in front of us, we are extremely pleased that the cash injection will help us to broaden our product range and to ramp up our sales and marketing efforts."

EUCODIS Bioscience' shareholders Pontis Capital, Wiener Wachstumsfonds, IBG, and ARAX participated in the cash injection.

Other news from the department manufacturing

More news from our other portals

All FT-IR spectrometer manufacturers at a glance